Kb-Lanra 1001: A Phase 1B/2 Study On Safety, Pk, Pd, And Preliminary Efficacy Of The Selective Syk Inhibitor Lanraplenib In Combination With The Flt3 Inhibitor Gilteritinib, In Flt3-Mutated R/R Aml
Gilteritinib;Lanraplenib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Kb-Lanra 1001: A Phase 1B/2 Study On Safety, Pk, Pd, And Preliminary Efficacy Of The Selective Syk Inhibitor Lanraplenib In Combination With The Flt3 Inhibitor Gilteritinib, In Flt3-Mutated R/R Aml ### Output: Gilteritinib;Lanraplenib